6-KThe Wire
GSK plc files 6-K
Filed Mar 30, 2026 · 3mo ago · Accession 0001654954-26-002919
Plain English
GSK plc announced that China's National Medical Products Administration (NMPA) has accepted for review a new drug application for bepirovirsen, an investigational treatment for chronic hepatitis B. This submission is supported by positive results from Phase III trials demonstrating functional cure rates.
Filing details
- Company
- GSK plc
- Ticker
- GSK
- CIK
- 1131399
- Form type
- 6-K
- Filing date
- Mar 30, 2026
- Report date
- Mar 30, 2026
- Document
- a5265y.htm
- Size
- 41 KB